FOLD
NASDAQAmicus Therapeutics Inc.
Price$14.48+0.14 (+1.01%)
2026-01-202026-04-23
News · 26 weeks47-67%
2025-10-262026-04-19
Mix1390d
- SEC Filings8(62%)
- Other3(23%)
- Earnings1(8%)
- Insider1(8%)
Latest news
25 items- SECSEC Form 8-K filed by Amicus Therapeutics Inc.8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
- INSIDERPresident and CEO Campbell Bradley L sold $322,839 worth of shares (22,500 units at $14.35), decreasing direct ownership by 2% to 998,680 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- SECAmicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form DEFA14A filed by Amicus Therapeutics Inc.DEFA14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form 10-K filed by Amicus Therapeutics Inc.10-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECAmicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- PRAmicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended December 31, 2025. Full-Year 2025 Financial Highlights: Total revenues for the full year 2025 were $634.2 million, reflecting strong operational growth measured at constant exchange rates
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
- PRAmicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium™ 2026. "Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our medicines at this year's WORLDSymposium. These new data add to the growing body of evidence supporting the important role of Galafold and Pombiliti + Opfolda," said Jeff Castelli, PhD, Chi
- SECSEC Form DEFM14A filed by Amicus Therapeutics Inc.DEFM14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECSEC Form DEFA14A filed by Amicus Therapeutics Inc.DEFA14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- SECAmicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- INSIDERPresident and CEO Campbell Bradley L exercised 75,000 shares at a strike of $6.10 and sold $1,073,182 worth of shares (75,000 units at $14.31) (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- ANALYSTAmicus Therapeutics downgraded by Jefferies with a new price targetJefferies downgraded Amicus Therapeutics from Buy to Hold and set a new price target of $14.50
- SECSEC Form PREM14A filed by Amicus Therapeutics Inc.PREM14A - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
- INSIDERChief Legal Officer Rosenberg Ellen covered exercise/tax liability with 43,109 shares, decreasing direct ownership by 8% to 464,601 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Development Officer Castelli Jeff covered exercise/tax liability with 30,007 shares, decreasing direct ownership by 7% to 409,311 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Accounting Officer Prout Samantha covered exercise/tax liability with 15,683 shares, decreasing direct ownership by 11% to 125,951 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief People Officer Clark David Michael covered exercise/tax liability with 23,879 shares, decreasing direct ownership by 10% to 221,811 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERPresident and CEO Campbell Bradley L covered exercise/tax liability with 108,602 shares, decreasing direct ownership by 10% to 1,021,180 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- INSIDERChief Financial Officer Harford Simon N.R. covered exercise/tax liability with 71,303 shares, decreasing direct ownership by 33% to 143,595 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- ANALYSTAmicus Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Amicus Therapeutics from Outperform to Market Perform and set a new price target of $14.50
- INSIDERChief People Officer Clark David Michael sold $363,380 worth of shares (25,642 units at $14.17), decreasing direct ownership by 9% to 245,690 units (SEC Form 4)4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
- ANALYSTAmicus Therapeutics downgraded by TD Cowen with a new price targetTD Cowen downgraded Amicus Therapeutics from Buy to Hold and set a new price target of $14.50